Stockreport

Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

Adamas Pharmaceuticals, Inc.  (ADMS) 
Last adamas pharmaceuticals, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.adamaspharma.com/investors
PDF EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the full commercial launch of its flagship product, GO [Read more]